Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS

Multiple Sclerosis Journal

Volumn 19, Issue 3, 2013, Pages 326-333

  Bosma, L V A E ^a   Kragt, J J ^a   Polman, C H ^a   Uitdehaag, B M J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

clinical outcome; Expanded Disability Status Scale; indicators of progression; long term outcome; Multiple sclerosis; patient reported outcome; PRO scales; prognosis; progressive MS; Timed 25 Foot Walk

Indexed keywords

BETA INTERFERON; GLATIRAMER; METHOTREXATE;

9 HOLE PEG TEST; ADULT; ARTICLE; COHORT ANALYSIS; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS IMPACT SCALE; MULTIPLE SCLEROSIS WALKING SCALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROSPECTIVE STUDY; SELF REPORT; TIME 25 FOOT WALK; WALKING SPEED;

EID: 84874347235     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512454346     Document Type: Article

References (19)

1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurol. 1983 ; 33: 1444-1552
2. Hobart J, Freeman J, Thompson A. Kurtzke scales revisited: The application of psychometric methods to clinical intuition. Brain. 2000 ; 123: 1027-1040
3. Sharrack B, Hughes RA, Soudain S, et al. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain. 1999 ; 122: 141-159
4. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999 ; 122: 871-882
5. Department of Health and Human Services, Food and Drug Administration. Guidance for industry, patient-reported outcome measures: Use in medical product development to support labelling claims, www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (2009, accessed 25 October, 2011).
6. Hobart J, Lamping D, Fitzpatrick R, et al. The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. Brain. 2001 ; 124: 962-973
7. Hobart JC, Riazi A, Lamping DL, et al. Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurol. 2003 ; 60: 31-36
8. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: A geographically based study 10: Relapses and long-term disability. Brain. 2010 ; 133: 1914-1929
9. Heesen C, Bohm J, Reich C, et al. Patient perception of bodily functions in multiple sclerosis: Gait and visual function are the most valuable. Mult Scler. 2008 ; 14: 988-991
10. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurol. 1996 ; 46: 907-911
11. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 1983 ; 13: 227-231
12. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria.". Ann Neurol. 2005 ; 58: 840-846
13. Lechner-Scott J, Kappos L, Hofman M, et al. Can the Expanded Disability Status Scale be assessed by telephone?. Mult Scler. 2003 ; 9: 154-159
14. Hoogervorst EL, Zwemmer JN, Jelles B, et al. Multiple Sclerosis Impact Scale (MSIS-29): Relation to established measures of impairment and disability. Mult Scler. 2004 ; 10: 569-574
15. Kalkers NF, De Groot V, Lazeron RH, et al. MS functional composite: Relation to disease phenotype and disability strata. Neurol. 2000 ; 54: 1233-1239
16. Hobart JC, Riazi A, Lamping DL, et al. Improving the evaluation of therapeutic interventions in multiple sclerosis: Development of a patient-based measure of outcome. Health Technol Assess. 2004 ; 8: iii 1-48
17. Kragt JJ, Thompson AJ, Montalban X, et al. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurol. 2008 ; 70: 1084-1091
18. Kremenchutzky M, Rice GP, Baskerville J, et al. The natural history of multiple sclerosis: A geographically based study 9: Observations on the progressive phase of the disease. Brain. 2006 ; 129: 584-594
19. Bosma LV, Kragt JJ, Brieva L, et al. The search for responsive clinical endpoints in primary progressive multiple sclerosis. Mult Scler. 2009 ; 15: 715-720